AU2017332789B2 - Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes - Google Patents

Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes Download PDF

Info

Publication number
AU2017332789B2
AU2017332789B2 AU2017332789A AU2017332789A AU2017332789B2 AU 2017332789 B2 AU2017332789 B2 AU 2017332789B2 AU 2017332789 A AU2017332789 A AU 2017332789A AU 2017332789 A AU2017332789 A AU 2017332789A AU 2017332789 B2 AU2017332789 B2 AU 2017332789B2
Authority
AU
Australia
Prior art keywords
rsv
leu
ile
lys
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017332789A
Other languages
English (en)
Other versions
AU2017332789A1 (en
Inventor
Ursula J. Buchholz
Peter L. Collins
Cyril LENOUEN
Steffen Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Codagenix Inc
United States Department of Health and Human Services
Original Assignee
Usa As Represented By Secretary
Codagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usa As Represented By Secretary, Codagenix Inc filed Critical Usa As Represented By Secretary
Publication of AU2017332789A1 publication Critical patent/AU2017332789A1/en
Application granted granted Critical
Publication of AU2017332789B2 publication Critical patent/AU2017332789B2/en
Priority to AU2021218112A priority Critical patent/AU2021218112B2/en
Priority to AU2022256195A priority patent/AU2022256195B2/en
Priority to AU2024203948A priority patent/AU2024203948B2/en
Priority to AU2026203425A priority patent/AU2026203425A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00061—Methods of inactivation or attenuation
    • C12N2760/00062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2017332789A 2016-09-23 2017-09-22 Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes Active AU2017332789B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2021218112A AU2021218112B2 (en) 2016-09-23 2021-08-19 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2022256195A AU2022256195B2 (en) 2016-09-23 2022-10-21 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2024203948A AU2024203948B2 (en) 2016-09-23 2024-06-11 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2026203425A AU2026203425A1 (en) 2016-09-23 2026-05-05 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662399133P 2016-09-23 2016-09-23
US62/399,133 2016-09-23
US201662400476P 2016-09-27 2016-09-27
US62/400,476 2016-09-27
PCT/US2017/053047 WO2018057950A1 (en) 2016-09-23 2017-09-22 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021218112A Division AU2021218112B2 (en) 2016-09-23 2021-08-19 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes

Publications (2)

Publication Number Publication Date
AU2017332789A1 AU2017332789A1 (en) 2019-05-09
AU2017332789B2 true AU2017332789B2 (en) 2021-05-27

Family

ID=60009756

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2017332789A Active AU2017332789B2 (en) 2016-09-23 2017-09-22 Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
AU2021218112A Active AU2021218112B2 (en) 2016-09-23 2021-08-19 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2022256195A Active AU2022256195B2 (en) 2016-09-23 2022-10-21 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2024203948A Active AU2024203948B2 (en) 2016-09-23 2024-06-11 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2026203425A Pending AU2026203425A1 (en) 2016-09-23 2026-05-05 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2021218112A Active AU2021218112B2 (en) 2016-09-23 2021-08-19 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2022256195A Active AU2022256195B2 (en) 2016-09-23 2022-10-21 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2024203948A Active AU2024203948B2 (en) 2016-09-23 2024-06-11 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2026203425A Pending AU2026203425A1 (en) 2016-09-23 2026-05-05 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes

Country Status (5)

Country Link
US (4) US10808012B2 (enExample)
EP (1) EP3515930A1 (enExample)
JP (3) JP7198759B2 (enExample)
AU (5) AU2017332789B2 (enExample)
WO (1) WO2018057950A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2900713A1 (en) 2013-02-08 2014-08-14 Steffen Mueller Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
AU2017332789B2 (en) 2016-09-23 2021-05-27 Codagenix, Inc. Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
JP2021508696A (ja) 2017-12-22 2021-03-11 コーダ−ジェニックス・インコーポレイテッドＣｏｄａ−Ｇｅｎｉｘ， Ｉｎｃ． がん処置のためのコドン対脱最適化領域を有する組換え型ウイルス及びその使用法
WO2019172982A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
WO2021231767A1 (en) 2020-05-13 2021-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rsv vaccine bearing one or more p gene mutations
WO2022011428A1 (en) * 2020-07-16 2022-01-20 Griffith University Live-attenuated virus vaccine
AU2022254738A1 (en) * 2021-04-08 2023-09-07 Codagenix Inc. Method of eliciting an immune response against respiratory syncytial virus
WO2025054424A1 (en) * 2023-09-06 2025-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human parainfluenza virus immunogenic molecules
WO2025128971A1 (en) * 2023-12-14 2025-06-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rsv vaccine bearing a polynucleotide which is de-optimised and de-attenuated

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150368622A1 (en) * 2013-02-08 2015-12-24 The United Of America, As Represented By Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224404A1 (de) 1982-06-30 1984-01-05 LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl Reibungskupplung sowie verfahren zu deren montage
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
DE69842165D1 (de) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
JP2002541785A (ja) 1999-04-13 2002-12-10 アメリカ合衆国 クローン化ヌクレオチド配列からの弱毒化キメラ呼吸系発疹ウイルスワクチンの製造
US20040161846A1 (en) 2000-11-22 2004-08-19 Mason Anthony John Method of expression and agents identified thereby
WO2006085987A2 (en) 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
EP2808384B1 (en) 2004-10-08 2017-12-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
PL2139515T5 (pl) 2007-03-30 2024-04-08 The Research Foundation Of The State University Of New York Atenuowane wirusy przydatne w szczepionkach
BRPI0921424A2 (pt) 2008-11-05 2016-01-05 Merck Sharp & Dohme vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica.
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
AU2017332789B2 (en) 2016-09-23 2021-05-27 Codagenix, Inc. Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150368622A1 (en) * 2013-02-08 2015-12-24 The United Of America, As Represented By Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C. LE NOUEN ET AL, "Attenuation of human respiratory syncytial virus by genome-scale codon-pair deoptimization", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, US, (2014-08-25), vol. 111, no. 36, pages 13169 - 13174 *

Also Published As

Publication number Publication date
JP2022188047A (ja) 2022-12-20
US20210188920A1 (en) 2021-06-24
JP2019534709A (ja) 2019-12-05
AU2021218112A1 (en) 2021-09-09
US11390651B2 (en) 2022-07-19
AU2017332789A1 (en) 2019-05-09
AU2021218112B2 (en) 2022-07-21
JP7862507B2 (ja) 2026-05-19
JP2025020142A (ja) 2025-02-12
US20220340619A1 (en) 2022-10-27
AU2024203948B2 (en) 2026-02-05
JP7198759B2 (ja) 2023-01-04
WO2018057950A1 (en) 2018-03-29
AU2026203425A1 (en) 2026-05-21
JP7573001B2 (ja) 2024-10-24
AU2024203948A1 (en) 2024-07-04
US20240417431A1 (en) 2024-12-19
US10808012B2 (en) 2020-10-20
EP3515930A1 (en) 2019-07-31
AU2022256195A1 (en) 2023-02-02
AU2022256195B2 (en) 2024-03-14
US12054519B2 (en) 2024-08-06
US20190233476A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
AU2021218112B2 (en) Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2020203460B2 (en) Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
JP7357709B2 (ja) さまざまな弱毒化表現型をもたらすｍ２－２ ｏｒｆにおける突然変異を含む組換えｒｓウイルス株
US11918638B2 (en) Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts
BR112018011674B1 (pt) Vírus sincicial respitatório (rsv) recombinante, seu método de produção, seus usos, bem como molécula de polinucleotídeo isolada, vetor e composição farmacêutica

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)